| 17.11 0.78 (4.78%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.4 | 1-year : | 25 |
| Resists | First : | 18.32 | Second : | 21.4 |
| Pivot price | 16.1  |
|||
| Supports | First : | 15.23 | Second : | 13.31 |
| MAs | MA(5) : | 16.27 |
MA(20) : | 16.27  |
| MA(100) : | 18.68 |
MA(250) : | 11.59 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 81.2 |
D(3) : | 72.8 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 30.39 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GYRE ] has closed below upper band by 17.9%. Bollinger Bands are 68.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.27 - 17.34 | 17.34 - 17.4 |
| Low: | 15.73 - 15.81 | 15.81 - 15.89 |
| Close: | 16.98 - 17.1 | 17.1 - 17.23 |
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Fri, 19 Apr 2024
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down to $15.41 - MarketBeat
Wed, 17 Apr 2024
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.1% - MarketBeat
Sat, 13 Apr 2024
Gyre Therapeutics Stock: Under The Radar Biotech Has A Shot At MASH Approval (NASDAQ:GYRE) - Seeking Alpha
Thu, 11 Apr 2024
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Markets Insider
Thu, 11 Apr 2024
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
Thu, 21 Mar 2024
Gyre Therapeutics appoints new board member By Investing.com - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 78.3 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 125 (K) |
| Shares Short P.Month | 140 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -82 % |
| Operating Margin | 7.5 % |
| Return on Assets (ttm) | 11.9 % |
| Return on Equity (ttm) | -113.5 % |
| Qtrly Rev. Growth | 5.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.27 |
| EBITDA (p.s.) | 0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 21 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 13.45 |
| Price to Cash Flow | 58.94 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 21% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|